IL6 and blood coagulation disease: 28-day mortality: 40.3% (TNF-α mAb) vs. 42.8% (placebo) (p = 0.27). Shock reversal/duration or prevention: NS difference.Coagulopathy ↓ with TNF-α mAb at day 7 (p < 0.001), day 28 (p = 0.005).Cytokines: No survival benefit baseline IL-6 or TNF-α. Safety: AEs similar, well tolerated; no anti-TNF-α mAb antibodies detected.